Prichard B
Proc R Soc Med. 2010; 70(Suppl 5):40-4.
PMID: 20919347
PMC: 1542839.
Rump A, Rosen R, Klaus W
Naunyn Schmiedebergs Arch Pharmacol. 1993; 348(4):431-4.
PMID: 7904053
DOI: 10.1007/BF00171344.
Brown A, Krause B, Morritt G
Thorax. 1981; 36(11):814-22.
PMID: 7330803
PMC: 471820.
DOI: 10.1136/thx.36.11.814.
Hillis W, Hutton I, Lawrie T
Br J Pharmacol. 1980; 68(3):373-9.
PMID: 7052333
PMC: 2044214.
DOI: 10.1111/j.1476-5381.1980.tb14550.x.
Jurgensen J, Frederiksen J, Hansen D
Br Heart J. 1981; 45(5):583-8.
PMID: 7016150
PMC: 482568.
DOI: 10.1136/hrt.45.5.583.
Pharmacokinetic and haemodynamic studies with labetalol in acute myocardial infarction.
Silke B, Nelson G, Ahuja R, Choudhury S, Taylor S
Ir J Med Sci. 1983; 152(5):179-86.
PMID: 6874287
DOI: 10.1007/BF02954714.
Comparative haemodynamic dose-response effects of intravenous propranolol and pindolol in patients with coronary heart disease.
Silke B, Nelson G, Ahuja R, Okoli R, Taylor S
Eur J Clin Pharmacol. 1983; 25(2):157-65.
PMID: 6628498
DOI: 10.1007/BF00543785.
Is the intrinsic sympathomimetic activity (ISA) of beta-blocking compounds relevant in acute myocardial infarction?.
Silke B, Verma S, Ahuja R, Hussain M, Hafizullah M, Reynolds G
Eur J Clin Pharmacol. 1984; 27(5):509-15.
PMID: 6151504
DOI: 10.1007/BF00556884.
Multi-lead electrocardiogram in relation to serum enzymes in acute myocardial infarction.
KROTKIEWSKI A, GAJEWSKA-LIPKA J, Szelemetko J, Ruszkowski J
Br Heart J. 1973; 35(10):991-6.
PMID: 4759476
PMC: 458742.
DOI: 10.1136/hrt.35.10.991.
Proceedings: The effects of practolol in the early stages of experimental myocardial infarction.
Marshall R, Parratt J
Br J Pharmacol. 1974; 52(1):124P.
PMID: 4451779
PMC: 1776938.
Effects of a combination of metoprolol and dazmegrel on myocardial infarct size in rats.
Bullock G, Lepran I, Parratt J, Szekeres L, Wainwright C
Br J Pharmacol. 1985; 86(1):235-40.
PMID: 4052726
PMC: 1916875.
DOI: 10.1111/j.1476-5381.1985.tb09454.x.
The management of hypertension.
Prichard B, OWENS C
Br J Clin Pharmacol. 1986; 21 Suppl 2:129S-142S.
PMID: 3530297
PMC: 1400731.
DOI: 10.1111/j.1365-2125.1986.tb02862.x.
Drug treatment of hypertension.
Prichard B
Drugs. 1988; 35 Suppl 6:40-52.
PMID: 3042360
DOI: 10.2165/00003495-198800356-00006.
Differences in haemodynamic response to beta-blocking drugs between stable coronary artery disease and acute myocardial infarction.
Silke B, Frais M, Verma S, Reynolds G, Taylor S
Eur J Clin Pharmacol. 1986; 29(6):659-65.
PMID: 2872054
DOI: 10.1007/BF00615955.
Letter: Myocardial infarction and metabolism.
Opie L
Br Med J. 1975; 2(5973):748.
PMID: 1139210
PMC: 1673927.
DOI: 10.1136/bmj.2.5973.748.
The incidence of myocardial infarction.
Lambert D
J R Coll Gen Pract. 1976; 26(170):635-42.
PMID: 978639
PMC: 2158375.
Comparative effects of propranolol and practolol in the early stages of experimental canine myocardial infarction.
Marshall R, Parratt J
Br J Pharmacol. 1976; 57(2):295-303.
PMID: 938798
PMC: 1667106.
DOI: 10.1111/j.1476-5381.1976.tb07479.x.
Effects of atenolol on regional myocardial blood flow and ST segment elevation in the canine myocardium.
Berdaux A, Bossier J, Giudicelli J
Br J Pharmacol. 1977; 60(3):433-9.
PMID: 890211
PMC: 1667297.
DOI: 10.1111/j.1476-5381.1977.tb07519.x.
Evaluation of evolution of myocardial infarction by serial determinations of serum creatine kinase activity.
Inoue M, Hori M, Fukui S, Abe H, Minamino T
Br Heart J. 1977; 39(5):485-92.
PMID: 861091
PMC: 483264.
DOI: 10.1136/hrt.39.5.485.
Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion.
Maroko P, Carpenter C, Chiariello M, Fishbein M, Radvany P, Knostman J
J Clin Invest. 1978; 61(3):661-70.
PMID: 641147
PMC: 372579.
DOI: 10.1172/JCI108978.
